KURTIS KLECAN: Open Payments
NPI 1154854008 · BELLEVILLE, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$526 in 28 payments from 13 companies in 2025. Trend: 2023 $465 · 2024 $636 · 2025 $526
Food & beverage: $526
| Company | Payments | Amount |
|---|---|---|
| Paratek Pharmaceuticals, Inc. | 6 | $103 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $63 |
| Otsuka America Pharmaceutical, Inc. | 2 | $58 |
| Viatris Specialty LLC | 3 | $45 |
| ABBVIE INC. | 2 | $43 |
| Xeris Pharmaceuticals, Inc. | 2 | $38 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $38 |
| Novo Nordisk Inc | 2 | $32 |
| AstraZeneca Pharmaceuticals LP | 2 | $31 |
| Supernus Pharmaceuticals, Inc. | 1 | $24 |
Products named: NUZYRA, CAPLYTA, REXULTI, YUPELRI, KEVEYIS, Kerendia, AIRSUPRA, Qelbree.
Industry payments across KS — which companies pay providers there.
